Herceptin's new formulation approved in Europe/Kadcyla to follow
Based on CPMP actions, see below, I predict Kadcyla will be approved before year end in Europe. Watch for IMGN stock to fly. I am surprised, IMGN is not flying now.
Basel, 2 September 2013
Roche’s new timesaving formulation of Herceptin approved in Europe for the treatment of HER2-positive breast cancer
Subcutaneous formulation is administered in two to five minutes, rather than 30 to 90 minutes with the standard intravenous form
Herceptin is used to treat more than 80,000 patients each year in Europe
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a new injectable (subcutaneous) formulation of Herceptin (trastuzumab) has been approved by the European Commission for the treatment of HER2-positive breast cancer, an aggressive sub-type of the disease. The approval is for both early and later stages of treatment.